Product ID: SQSG35I2011
Report ID:
SQSG35I2011 |
Region:
Global |
Published Date: April, 2024
Pages:
157
|
Tables:
90 |
Figures:
76
Global schizophrenia drugs market is dominated by Asia pacific region. Many manufacturers on the market are concentrating on research and development efforts to create safer and more effective medications to treat mental disorders. Key players are also attempting to enter into agreements, colorations, and acquisitions to broaden their product range in order to meet the soaring demand for anti-anxiety and anti-depression medications.
For instance, an Indian multinational pharmaceutical company named Sun Pharmaceutical Industries Ltd. announced in 2022 that it had entered into a licensing agreement with a pharmaceutical company based in Denmark to introduce cutting-edge anti-depression medications under the trade name Vortidiftm in India. Numerous of these changes are predicted to benefit the market for psychotropic medications in the Asia Pacific except in China and Japan. In the region of North America, the market is lately been in a declining phase because of decreasing demand for schizophrenia drugs.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONGlobal Schizophrenia Drugs Market size was valued at USD 7.16 billion in 2019 and is poised to grow from USD 7.58 billion in 2023 to USD 12.58 billion by 2031, growing at a CAGR of 5.8% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQSG35I2011